Javascript must be enabled to continue!
STK4 antisense RNA 1-p53 affects osteosarcoma
View through CrossRef
Abstract
Background
LncRNA STK4 antisense RNA 1(STK4-AS1) has been identified as a potential biomarker associated with multiple cancers. We proposed that STK4-AS1 plays a role in the proliferation of osteosarcoma by regulating the cell cycle.
Methods
We compared the expression of STK4-AS1, p53, and p21 in osteosarcoma vs normal samples in clinical tissues and cell lines. We determined the effect of overexpression and knockdown of STK4-AS1 in p53 expressing osteosarcoma cells U2OS, p53 muted osteosarcoma cells MG63, and osteoblast cells hFOB on p53 and p21 expression and the cell viability. For U2OS and MG63, the cell cycle was analyzed and the expression of cyclin proteins was determined. We overexpressed p53 or p21 in STK4-AS1 overexpressed cells to explore the association of STK4-AS1 and p53 in U2OS.
Results
The STK4-AS1 expression was higher and p53 and p21 expression were lower in osteosarcoma tissue and cells than in their non-cancer counterparts. The expression of STK4-AS1 was negatively correlated with the expression of p53 or p21. Knockdown of STK4-AS1 in U2OS decreased the cell viability, increased cells in the G0/G1 phase, decreased cells in the S and G2/M phase, decreased expression of cyclin A and B, increased p53 and p21, and had no effect on cyclin D and cyclin E, while overexpression of STK4-AS1 did the opposes. Overexpression of p53 or p21 recovered some changes caused by STK4-AS1 overexpression in U2OS. MG63 expressed no p53 and the expression of p21, cyclin A, and cyclin B, cell viability, and cell cycle were not affected by altered STK4-AS1 levels. In hFOB cells, the expression of p53 and p21 was decreased and the cell viability was increased when STK4-AS1 was overexpressed, but they were not affected when STK4-AS1 was knocked down.
Conclusion
LncRNA STK4-AS1 promoted the cell cycle of osteosarcoma cells by inhibiting p53 expression.
Title: STK4 antisense RNA 1-p53 affects osteosarcoma
Description:
Abstract
Background
LncRNA STK4 antisense RNA 1(STK4-AS1) has been identified as a potential biomarker associated with multiple cancers.
We proposed that STK4-AS1 plays a role in the proliferation of osteosarcoma by regulating the cell cycle.
Methods
We compared the expression of STK4-AS1, p53, and p21 in osteosarcoma vs normal samples in clinical tissues and cell lines.
We determined the effect of overexpression and knockdown of STK4-AS1 in p53 expressing osteosarcoma cells U2OS, p53 muted osteosarcoma cells MG63, and osteoblast cells hFOB on p53 and p21 expression and the cell viability.
For U2OS and MG63, the cell cycle was analyzed and the expression of cyclin proteins was determined.
We overexpressed p53 or p21 in STK4-AS1 overexpressed cells to explore the association of STK4-AS1 and p53 in U2OS.
Results
The STK4-AS1 expression was higher and p53 and p21 expression were lower in osteosarcoma tissue and cells than in their non-cancer counterparts.
The expression of STK4-AS1 was negatively correlated with the expression of p53 or p21.
Knockdown of STK4-AS1 in U2OS decreased the cell viability, increased cells in the G0/G1 phase, decreased cells in the S and G2/M phase, decreased expression of cyclin A and B, increased p53 and p21, and had no effect on cyclin D and cyclin E, while overexpression of STK4-AS1 did the opposes.
Overexpression of p53 or p21 recovered some changes caused by STK4-AS1 overexpression in U2OS.
MG63 expressed no p53 and the expression of p21, cyclin A, and cyclin B, cell viability, and cell cycle were not affected by altered STK4-AS1 levels.
In hFOB cells, the expression of p53 and p21 was decreased and the cell viability was increased when STK4-AS1 was overexpressed, but they were not affected when STK4-AS1 was knocked down.
Conclusion
LncRNA STK4-AS1 promoted the cell cycle of osteosarcoma cells by inhibiting p53 expression.
Related Results
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2
The AP-1 protein complex primarily consists of several proteins from the c-Fos, c-Jun, activating transcription factor (ATF), and Jun dimerization protein (JDP) families. JDP2 has ...
Antisense Technology
Antisense Technology
Abstract
Antisense technology is a powerful procedure that permits the controlled silencing of a specific gene for investigations of mRNA and protein function. This ...
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract 1261: Targeting IL-11Rα inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model
Abstract
Osteosarcoma is the most common primary tumor of bones. In the past three decades treatment paradigms and survival rates have not improved. While osteosarco...
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract A18: Comprehensive identification of bone cancer driver genes by using Li-Fraumeni syndrome iPSCs
Abstract
Osteosarcoma, the primary malignant tumor of bone, is the most frequent primary non-hematologic malignancy in children and adolescents. Despite the advances...
Abstract 1716: A small molecule corrector for p53 mutants found in cancer
Abstract 1716: A small molecule corrector for p53 mutants found in cancer
Abstract
p53 is the main tumor suppressor protein in vertebrates and the most frequently mutated gene in human cancers. The majority of p53 mutations are missense mu...
Abstract 1728: Overactivation of tumor suppressor P53 in hepatocytes promotes hepatocarcinogenesis
Abstract 1728: Overactivation of tumor suppressor P53 in hepatocytes promotes hepatocarcinogenesis
Abstract
Aim: p53 is a tumor suppressor and its dysfunction promotes carcinogenesis of several organs including the liver. Meanwhile, p53 is reported to be overactiv...


